KR20190088758A - Anti-atopic composition comprising extract of Geomgangsong thinning by-product as effective component - Google Patents

Abstract

The present invention relates to an anti-atopic composition containing an extract of a Pinus densiflora thinning by-product as an active component. Since the extract of the Pinus densiflora thinning by-product has an excellent effect of remarkably reducing the expression of β-hexosaminidase by T-cell activity and inhibiting the expression of histamine, compared to a pine needle and a pine gnarl, a composition containing the extract of the Pinus densiflora thinning by-product as the active component can be usefully used as health functional food for preventing or alleviating atopic dermatitis, cosmetics for atopic dermatitis, or a therapeutic agent for atopic dermatitis.

Description

[0001] The present invention relates to an anti-atopic composition comprising extracts of by-

The present invention relates to an anti-atopic composition comprising as an active ingredient an extract of a by-product of crimson thinning.

Atopic dermatitis is caused by genetic, environmental, and immunological causes. It is an allergic disease that develops in the stratum corneum that acts as a protective barrier from the outermost part of the skin and becomes worse in a dry climate. Atopic dermatitis has a worldwide prevalence rate of 10 ~ 20%. It usually occurs in infants between 1 month and 1 year old. When they are 3 years old, it is alleviated to some extent.

The main symptoms of atopic dermatitis are severe itching, skin dryness, rash, dirt, scabs and scaly skin (rabbits). The itching that causes feelings of scratching is induced by itch mediators such as histamine. In the case of normal people, the symptoms are easily alleviated by scratching. In the case of atopic patients, however, Scratches. These scratching behaviors of atopic patients may cause skin barriers to collapse and secondary infections leading to further deterioration of inflammation. Atopic dermatitis can be temporarily alleviated, but it can be recurred due to environmental stimuli such as the environment and food, which can be exacerbated, and deterioration and mitigation are repeated.

The cause of atopic dermatitis is not well known, but it has been found to be related to the immune response, mainly due to a large number of genetic factors. In addition, dry skin, characteristic of easily itching of the skin compared with normal people, infection by bacteria, viruses, Emotional factors and environmental factors seem to work together. The inflammation associated with atopic dermatitis may be due to excessive immune cell action resulting in inflammatory cytokines such as TNF-α, tumor necrosis factor-α and interleukin-1 (IL-1, interleukin-1) (ROS), such as radicals (OH), superoxide radicals (O ₂ -), hydrogen peroxide (H ₂ O ₂ ) and the like.

In addition, mast cells are known as the key cells causing acute and chronic inflammatory diseases in most allergic diseases including atopic dermatitis. When mast cells are activated, they release inflammatory cytokines such as TNF-α, IL-1 and IL-6, as well as pruritogens such as histamine. Thus, inflammatory cytokines derived from mast cells further promote the inflammatory reaction, while promoting the secretion of itch-like substances such as histamine, thereby causing skin barrier disruption. Thus, identifying substances that can inhibit inflammatory cytokines and itch-mediated substances without side effects will be effective in controlling allergic diseases, including atopic dermatitis.

The prescription for atopic dermatitis is mainly drug therapy such as steroids, antihistamines, antibiotics and the like. Steroids (adrenocorticosteroids) are largely anti-inflammatory and immunosuppressive and have excellent effects, but when applied for a long time, side effects such as skin weakness, systemic hormone symptoms, and addiction may occur. The current treatment for atopic dermatitis is to use immunosuppressants and new antihistamines. However, antihistamines alone can not completely block allergic reactions. This is because histamine is not the only chemical messenger that causes allergic reactions. Therefore, it is required to develop a composition for treating atopic dermatitis which is effective for atopic dermatitis but has no side effects.

On the other hand, geumgangsong (Pinus desiflora for. erecta) distributed widely in Uljin, Bonghwa-gun area in northern part of Gyeongbuk and Gangneung and Samcheok in southern part of Gangwon, along the Taebaek mountain range in the valley and mountain ridge of Mt. Kumgang. However, it was greatly damaged by logging and firing. Today, Is the largest in Korea. Pine trees are native to Korea, Japan, and Manchuria, and all parts such as leaves, pine cones, In particular, pine leaves that can be easily harvested have been used in folk remedies and have been used as health foods for the treatment of adult diseases such as hypertension, diabetes, skin diseases and neuralgia, and for longevity.

Geumgang Song, which is a native of Uljin, is producing an unlimited amount of thinning by-products due to the continuous thinning work for the creation of tourist sites and the management and management of Uljin area. Most by-products are used for composting and sawdust production. Although there are many reports on the functionality of the bryophytes, there is no active study on the functionality of the mixture of bryophytes and bryophytes. By studying the functionality of thinning byproducts that are economically viable as an insoluble resource, they can be used as a new source of income by developing functional foods and high value-added products.

Korean Patent Laid-Open Publication No. 2017-0045085 discloses a composition for improving skin comprising pine bark extract and its use, but it has not been disclosed about an anti-atopic composition containing an extract of a goldsmith's shrimp by-product of the present invention as an effective ingredient .

The present invention provides an anti-atopic composition comprising an extract of a by-product of Kumkang Shipping as an active ingredient. The present invention also provides an anti-atopic composition comprising an extract of Baekjanggwon , The effect of inhibiting the secretion of beta -hexosaminidase was remarkable, confirming that there was a synergistic effect, thereby completing the present invention.

In order to solve the above problems, the present invention provides a health functional food composition for preventing or ameliorating atopic dermatitis, which comprises an extract of a goldsmith's thinning by-product as an active ingredient.

In addition, the present invention provides a cosmetic composition for preventing or improving atopic dermatitis containing an extract of a by-product of goldsmith's shrimp as an active ingredient.

The present invention also provides a pharmaceutical composition for the prevention or treatment of atopic dermatitis, which comprises an extract of a gold mining shrimp by-product as an active ingredient.

The present invention relates to an anti-atopic composition comprising as an active ingredient an extract of a goldsmith's blood thinning by-product, wherein the extract of the goldsmith's blood thinning by-product contains β-hexosaminidase secretion, histamine secretion, IL -4 and TNF- [alpha] secretion, the composition comprising the extract of the present invention as an active ingredient can be used as a health functional food for prevention or improvement of atopic dermatitis, a cosmetic for atopic dermatitis or a treatment for atopic dermatitis Can be used.

FIG. 1 shows the results of cytotoxicity of by-products of shrimp silkworm, shrubs and mullet. CON is a negative control.
FIG. 2 shows the results of confirming the inhibitory effect of β-hexosaminidase production on the by-products of shrimp silkworms, shrubs and gypsum. CON was a negative control and induced beta-hexosaminidase production using PA (100 pg / ml of PHORBOL 12-MYRISTATE 13-ACETATE (PMA) and 1 μM of Calcium Ionophore A23187).
FIG. 3 shows the result of confirming the inhibitory effect of histamine secretion by the by-product of the goldsmith's shrimp. CON was a negative control and promoted histamine release using PA (100 pg / ml of PHORBOL 12-MYRISTATE 13-ACETATE (PMA) and 1 μM of Calcium Ionophore A23187).
FIG. 4 shows the results of confirming the suppressive effect of inflammatory cytokines (IL-4 and TNF-α) secreted by the goldsmith thinning by-products. CON was a negative control and induces the expression of inflammatory cytokines using PA (100 pg / ml of PHORBOL 12-MYRISTATE 13-ACETATE (PMA) and 1 μM of Calcium Ionophore A23187).

The present invention relates to a health functional food composition for preventing or ameliorating atopic dermatitis, which contains an extract of a gold mining shrimp by-product as an active ingredient.

The shoemaking by-product of the shoemakers is composed of a mixture of bamboo leaves and jade shrubs, preferably bamboo shrubs and shrubs at a weight ratio of 1 to 3: 0.5 to 2, Is to mix the barycus and the moon cake at a weight ratio of 2: 1, but the present invention is not limited thereto.

In one preferred embodiment of the present invention, the concentration of the extract of the goldsmith thinning by-products in the composition may be 100 μg / ml or more, preferably 150 to 250 μg / ml, more preferably 200 μg / It does not.

In a preferred embodiment of the present invention, the extract of the gold wire harvest thinning by-product is extracted by using water, C ₁ -C ₄ lower alcohol or a mixture thereof as a solvent, more preferably extracting But is not limited thereto.

The health functional food composition for preventing or ameliorating atopic dermatitis of the present invention may be manufactured by any one of formulations selected from granules, rings, tablets, capsules, candies, syrups and beverages, but is not limited thereto. The health functional food composition is not particularly limited as long as it can be ingested to prevent or ameliorate atopic dermatitis.

When the health functional food composition of the present invention is used as a food additive, the health functional food composition may be added as it is, or may be used together with other food or food ingredients, and suitably used according to a conventional method. The active ingredient may be suitably used depending on its intended use (prevention or improvement). However, in the case of long-term intake for the purpose of controlling health, it can be used in an amount that does not cause any safety problems. There is no particular limitation on the kind of the food. Examples of the foods to which the health functional food composition can be added include dairy products including meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen and other noodles, gums, ice cream, soups, Drinks, alcoholic beverages, and vitamin complexes, all of which include health foods in a conventional sense.

In addition, the health functional food composition of the present invention can be produced as a food, particularly a functional food. The functional food of the present invention includes components that are ordinarily added in food production, and includes, for example, proteins, carbohydrates, fats, nutrients, and seasonings. For example, in the case of a drink, a natural carbohydrate or a flavoring agent may be included as an additional ingredient in addition to the active ingredient. The natural carbohydrate may be selected from the group consisting of monosaccharides (e.g., glucose, fructose, etc.), disaccharides (e.g., maltose, sucrose etc.), oligosaccharides, polysaccharides (e.g., dextrin, cyclodextrin, , Xylitol, sorbitol, erythritol, etc.). The flavoring agent may be a natural flavoring agent (e.g., tau Martin, stevia extract, etc.) and a synthetic flavoring agent (e.g., saccharin, aspartame, etc.). In addition to the above-mentioned health functional food composition, it is possible to use various nutrients, vitamins, electrolytes, flavors, colorants, pectic acid and salts thereof, alginic acid and its salts, organic acids, protective colloid thickening agents, pH adjusting agents, stabilizers, preservatives, glycerin, A carbonating agent used in beverages, and the like.

In addition, the present invention provides a cosmetic composition for preventing or improving atopic dermatitis containing an extract of a by-product of goldsmith's shrimp as an active ingredient.

In the cosmetic composition for improving atopic dermatitis according to the present invention, the cosmetic composition for improving atopic dermatitis may be in the form of a solution, suspension, emulsion, paste, gel, cream, lotion, powder, soap, surfactant-containing cleansing oil, powder foundation, A cream, a softener, a nutrient lotion, a pack, an essence, a hair tonic, a shampoo, a rinse, a hair conditioner, a hair conditioner, a hair conditioner, Lotion, milk lotion, moisturizing lotion, nutrition lotion, massage cream, nutritional cream, eye cream, moisturizing cream, hand cream, foundation, nutrition essence, sunscreen, skin lotion, skin toner, , Soaps, cleansing foams, cleansing lotions, cleansing creams, body lotions and body cleansers You can have a single dosage form slow, but not limited to this. The composition of each of these formulations may contain various kinds of bases and additives necessary for formulation of the formulation, and the kinds and amounts of these ingredients can be easily selected by those skilled in the art.

When the formulation of the present invention is a paste, cream or gel, animal fibers, plant fibers, wax, paraffin, starch, tracant, cellulose derivatives, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide are used as carrier components . In the case where the formulation of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as a carrier component. Especially, in the case of a spray, a mixture of chlorofluorohydrocarbons, propane / Propane or dimethyl ether. In the case of the solution or emulsion of the present invention, a solvent, a solvent or an emulsifier is used as a carrier component, and examples thereof include water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, , 3-butyl glycol oil, glycerol aliphatic ester, polyethylene glycol or sorbitan fatty acid esters.

When the formulation of the present invention is a suspension, a carrier such as water, a liquid diluent such as ethanol or propylene glycol, a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, Cellulose, aluminum metahydroxide, bentonite, agar or tracant, etc. may be used. When the formulation of the present invention is an interfacial active agent-containing cleansing, the carrier component is selected from aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyltaurate, sarcosinate, fatty acid amide Ether sulfates, alkylamidobetaines, aliphatic alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, linolenic derivatives or ethoxylated glycerol fatty acid esters.

The present invention also provides a pharmaceutical composition for the prevention or treatment of atopic dermatitis, which comprises an extract of a gold mining shrimp by-product as an active ingredient.

The pharmaceutical composition for preventing or treating atopic dermatitis of the present invention may further comprise a suitable carrier, excipient or diluent conventionally used in the production of a pharmaceutical composition. The pharmaceutical dosage forms of the compositions according to the invention may be used alone or in combination with other pharmaceutically active compounds as well as in suitable combinations.

The pharmaceutical composition according to the present invention may be formulated in the form of powders, granules, tablets, capsules, oral preparations such as suspensions, emulsions, syrups and aerosols, external preparations, suppositories and injections according to conventional methods . Examples of carriers, excipients and diluents that can be included in the pharmaceutical composition including the extract of the goldsmith thinning by-product include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin , Calcium phosphate, calcium silicate, cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil, etc. . In the case of formulation, a diluent or excipient such as a filler, an extender, a binder, a wetting agent, a disintegrant, or a surfactant is usually used. Solid formulations for oral administration include tablets, pills, powders, granules, capsules and the like, which may contain at least one excipient such as starch, calcium carbonate, sucrose or lactose, Gelatin and the like. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Examples of liquid formulations for oral use include suspensions, solutions, emulsions and syrups. In addition to water and liquid paraffin, which are commonly used simple diluents, various excipients such as wetting agents, sweeteners, fragrances, preservatives and the like have. Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories. Examples of the suspending agent include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like. Examples of the suppository base include withexol, macrogol, tween 61, cacao butter, laurin, glycerogelatin and the like.

The preferred dosage of the pharmaceutical composition of the present invention varies depending on the condition and the weight of the patient, the degree of disease, the drug form, the administration route and the period, but can be appropriately selected by those skilled in the art. The pharmaceutical composition of the present invention can be administered to mammals such as rats, mice, livestock, humans, and the like in various routes. All modes of administration may be expected, for example, by oral, rectal or intravenous, intramuscular, subcutaneous, intra-uterine or intracerebroventricular injections.

Hereinafter, the present invention will be described in more detail with reference to Preparation Examples and Examples. It is to be understood by those skilled in the art that these preparations and examples are merely intended to explain the present invention more specifically and that the scope of the present invention is not limited thereto.

Manufacturing example  1. Manufacture of extracts of by-products

The shrubs and shrubs collected at the fall of 2015 were mixed at a weight ratio of 2: 1. The collected by - products were washed and dried and then crushed. Thereafter, 10 parts by weight of 70% (v / v) ethanol was added per 1 part by weight of the sample, followed by stirring at room temperature for 10 hours. After stirring, the supernatant and the precipitate were separated by Whatman No.1 filter paper, concentrated and lyophilized, and stored in a refrigerated room. The extracts of Seokbyeon and Seokbyeon were also extracted by using the same method as the extracts of Gangwon -

Example  1. Identification of cell viability

RBL-2H3 (Rat Basophil Leukemia) cells distributed from the ATCC (American Type Culture Collection) were cultured in DMEM medium. In order to determine the concentration range to be used in the experiment, MTT (3- (4,5-dimethylthiazol-2-yl) -methanone was prepared by treating Mosman (1983) -2,5-diphenyltet razolium bromide) analysis.

RBL-2H3 cells were cultured in a 96-well plate with 100 占 퐇 of DMEM medium for one day, and treated with various concentrations (50, 100 and 200 占 퐂 / ml) of the sample of Preparation Example 1 for 24 hours. 10 μl of 5 mg / ml MTT solution was added to each well, followed by incubation for 3 hours to induce a reduction reaction. 100 μl of DMSO (dimethyl sulfoxide) solution was added to purify the formazan crystals completely Lt; / RTI > The degree of color development was measured at 570 nm using a spectrophotometer, and the relative cell viability of the sample treated group was calculated based on the survival rate of 100% of the untreated group in which only the cells were cultured.

As a result, as shown in FIG. 1, it was confirmed that the cytotoxicity of the goldsmiths by-product, bryophytes, and mosses was not observed up to 200 μg / ml.

Example  2. Beta- Hexosaminidase (β- hexosaminidase ) Expression Low performance  Confirm

RBL-2H3 cells were plated on a 24-well plate at 3 × 10 ⁵ cells per well and cultured for 24 hours. After that, PA (100 pg / ml of PHORBOL 12-MYRISTATE 13-ACETATE (PMA) and 1 μM of Calcium Ionophore A23187) was treated to induce production of beta-hexosaminidase and the sample of Preparation Example 1 50 mM Tris-HCl (pH 7.0), and then incubated for 1 hour. The reaction was stopped by ice for 10 minutes, and then 1 mM 4-Nitrophenyl N-acetyl-β-D-glucosaminide ) Substrate for 1 hour, absorbance was measured at 405 nm with a stop reagent (0.1 M Carbonate buffer).

As a result, as shown in FIG. 2, when 200 μg / ㎖ of the shrimp thinning by-products were treated, the secretion of beta-hexosaminidase was further reduced, Was synergistic in the treatment of atopy.

Example  3. Identification of histamine inhibitory effect of by-products

RBL-2H3 cells were plated on a 24-well plate at 3 × 10 ⁵ cells per well and cultured for 24 hours in order to confirm the effect of the goldsmith thinning by-product extract on histamine secreted by degranulation. After that, PA (100 pg / ml of PHORBOL 12-MYRISTATE 13-ACETATE (PMA) and 1 μM of Calcium Ionophore A23187) were treated and the samples of Preparation Example 1 were treated with each concentration (50, 100 and 200 μg / And incubated for 1 hour to liberate histamine. The reaction was terminated on ice for 10 min to terminate the reaction. Histamine concentration was measured using a histamine assay kit (Histamine ELISA kit, abcam) using the culture supernatant.

As a result, as shown in FIG. 3, it was confirmed that the concentration of histamine released from the cell, which was increased by PA, decreased when the cryptomeria waste by-product was treated.

Example  4. Confirmation of suppression of inflammatory cytokine secretion of by-product

To measure the levels of IL-4 and TNF-a secreted in mast cells, RBL-2H3 cells were plated in 24 well plates and cultured for 24 hours. After that, PA (100 pg / ml of PHORBOL 12-MYRISTATE 13-ACETATE (PMA) and 1 μM of Calcium Ionophore A23187) were treated and the samples of Preparation Example 1 were treated with each concentration (50, 100 and 200 μg / And cultured for 1 hour to induce IL-4 and TNF-a expression. After completion of the incubation, the supernatant was centrifuged (1200 rpm, 5 minutes) and the content was measured using an IL-4 and TNF-α kit (ELISA kit, R & D) .

As a result, as shown in FIG. 4, it was confirmed that the secretion of IL-4 and TNF-α was inhibited by the treatment of the by-product of the shrimp thinning by shrimp. Especially, when the extract of Kumkang shrimp by-product was treated at a concentration of 200 μg / Secretion inhibitory effect was excellent.

Claims (6)

A pharmaceutical composition for the prevention or treatment of atopic dermatitis, which comprises an extract of Kumkang Shimpo by-product as an active ingredient. The pharmaceutical composition for preventing or treating atopic dermatitis according to claim 1, wherein the by-product of the gold-smelting thinning is composed of a mixture of bamboo leaves and gypsum in a pearl lining. [Claim 3] The pharmaceutical composition according to claim 2, wherein the mixture of bark and jelly is mixed at a weight ratio of 1: 3: 0.5: 2. The pharmaceutical composition according to claim 1, wherein the extract inhibits the expression of beta-hexosaminidase and histamine. A cosmetic composition for preventing or ameliorating atopic dermatitis containing as an active ingredient an extract of a by-product of Kumkang Shipping A health functional food composition for prevention or amelioration of atopic dermatitis, which comprises an extract of Ganghwasong liverwort byproduct as an active ingredient.

Images